Abstract
Alopecia areata (AA) is an autoimmune disease affecting people of all ages. There is currently no cure for AA, and a highly efficacious therapy for severe AA has been elusive. Recently, scientific advances have identified the Janus kinase pathway as a target for treatment. Both Janus kinase inhibitors approved by the US Food and Drug Administration, tofacitinib and ruxolitinib, have shown promise in open-label clinical trials. This review summarizes the results of long-term use of tofacitinib in severe AA.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Administration, Topical
-
Adolescent
-
Adult
-
Algorithms
-
Alopecia Areata / drug therapy*
-
Autoimmune Diseases / drug therapy
-
Clinical Trials as Topic
-
Female
-
Humans
-
Janus Kinase Inhibitors / administration & dosage
-
Janus Kinase Inhibitors / therapeutic use*
-
Male
-
Piperidines / administration & dosage
-
Piperidines / therapeutic use*
-
Pyrimidines / administration & dosage
-
Pyrimidines / therapeutic use*
-
Pyrroles / administration & dosage
-
Pyrroles / therapeutic use*
Substances
-
Janus Kinase Inhibitors
-
Piperidines
-
Pyrimidines
-
Pyrroles
-
tofacitinib